Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02518594 · ClinicalTrials.gov registry record · Phase 3

A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix

A Phase 3 study, sponsored by The George Washington University Biostatistics Center.

Completed
Registry status
Phase 3
Development phase
1,311
Enrollment target

NCT02518594 is a Phase 3 study that has completed, run by The George Washington University Biostatistics Center. The registered enrollment target is 1,311 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02518594, a Phase 3 study, has completed, sponsored by The George Washington University Biostatistics Center.

COMPLETED
Registry status
Phase 3
Development phase
1,311 participants
Enrollment target

Study Summary

This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.

Interventions

  • DRUG Placebo
  • DRUG Vaginal progesterone
  • DEVICE Arabin Pessary

Trial Details

FieldValue
Enrollment Target 1,311 participants
Start Date 2015-11-13
Est. Completion 2025-02-18
Phase Phase 3

What the Registry Record Tells You About NCT02518594

The ClinicalTrials.gov registry entry for NCT02518594 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The George Washington University Biostatistics Center, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02518594 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02518594 about?

NCT02518594 is a clinical study titled "A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix". This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.

What is the current status of trial NCT02518594?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,311 participants. The study started on 2015-11-13. Estimated completion is 2025-02-18.

What interventions are being tested in trial NCT02518594?

The interventions under investigation include: Placebo (DRUG), Vaginal progesterone (DRUG), Arabin Pessary (DEVICE).

Who is sponsoring clinical trial NCT02518594?

This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.